Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The FDA approved Lenacapavir, the first twice-a-year injection to prevent HIV, marking a historic step in public health. Mistr, an LGBTQIA+-owned platform known for making sexual healthcare accessible ...

Lenacapavir is the latest HIV prevention shot to receive FDA approval. Apretude , made by GSK’s ViiV Healthcare, was the first injectable pre-exposure prophylaxis medication to receive approval ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

From treatment to prevention. Lenacapavir was approved by the FDA in 2022 to treat people with HIV whose virus has become resistant to other antiviral drugs. As they were developing that treatment ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

The FDA's decision makes lenacapavir available today in the U.S., which sees about 31,000 of the 1.3 million new HIV infections each year worldwide.

The FDA approved lenacapavir last week. Patients need just two injections of it a year to get that protection, but as NPR's Jonathan Lambert explains, its high price could limit its power to stop ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Gilead Sciences submitted a new drug application to the FDA for the approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor that is given subcutaneously every 6 months.